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Introduction 
Thrombocytopenia in patients with acute 
systemic lupus erythematosus (SLE) 
frequently presents to the clinician with 
considerable diagnostic and therapeutic 
difficulties. SLE patients with thrombo-
cytopenia are more likely to have significant 
organ damage such as in the heart, kidneys, 
or the central nervous system.1  
 
Case Report 
A 62-year-old Vietnamese woman was 
admitted to the hospital with a one-month 
history of high-grade fever (up to 104oF), 
decreased appetite, nausea, postprandial 
vomiting, and worsening abdominal pain. 
She previously had two days of mucus-like 
diarrhea. Her past medical history included 
primary hypothyroidism. 
This patient visited Vietnam on a 
number of occasions, most recently 
returning two months prior to admission 
after a six-month stay.  While in Vietnam, 
she developed fatigue. Upon her return to 
the US, she was progressively more tired 
and weak with diminished appetite. She 
reported progressive shortness of air 
beginning about four to five weeks prior to 
her hospital admission with associated 
chills, fever, severe diaphoresis, and a dry 
cough.   She was given a week of antibiotic 
therapy at that time without relief.   
 
 
Ten days prior to admission, she was 
admitted to another hospital, where an 
esophagogastroduodenoscopy and a 
Camplyobacter-like organism (CLO) test for 
Helicobacter pylori were negative. An 
echocardiogram revealed moderate mitral 
and mild tricuspid insufficiency and a 
normal ejection fraction of 51%.  A CT scan 
of the abdomen and pelvis was negative.  
CT angiography of the chest revealed 
bibasilar scarring, pleural thickening, and 
atelectasis. She had scattered axillary lymph 
nodes at the upper limits of normal size 
(right greater than left), breast nodules, and 
a positive Antinuclear Antibody test (ANA).  
She was dismissed on acetaminophen, 
sucralfate, and a proton pump inhibitor with 
recommendations for outpatient colon-
oscopy and follow-up with her primary care 
physician. Her symptoms persisted and 
increased over a one-week period.  Thus, 
she presented at our hospital.  
At the time of admission, she was 
pyrexial (100.6°F) and tachycardic (105 
beats per minute). Her respiratory rate was 
18, her oxygen saturation was 94% on room 
air, and her blood pressure was 153/93 
mmHg.  She had very dry mucous mem-
branes with poor dentition. She had mild 
rhonchi on her right lower lobe with no 
wheezes or crackles. She had normal S1 and 
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S2 heart sounds with no murmur. Her 
abdomen was soft with positive bowel 
sounds.  She had positive peripheral pulses 
without lower leg edema.  She had a few 
small petechiae on her lower extremities. 
The initial investigation revealed a 
normocytic anemia with a platelet count of 
133,000.  Over a few days, the platelets 
decreased to 21,000.  She had a high 
erythrocyte sedimentation rate (ESR of 90), 
hematuria, proteinuria, a positive ANA 
(anti-histone, anti-Sm, and anti-Sjögren's 
syndrome A and B were high) along with a 
low C3 and C4, positive platelet antibodies, 
a positive direct Coomb’s test, positive IgM 
and IgG for Helicobacter pylori, and a small 
pericardial effusion on the 2D 
echocardiogram. 
During her hospitalization, she received 
the following medications: 
 two pulse therapy IV methyl-
prednisolone, 125mg every six hours for 
two days and 1g daily for three days,  
 oral prednisone, 60mg daily,  
 mycophenolate mofetil, 500mg twice 
daily,  
 hydroxychloroquine, 200mg twice daily, 
 intravenous immunoglobulin (IVIG), 
400mg/kg for five days,  
 rituximab, three doses,  
 triple therapy for H. pylori 
(clarithromycin, amoxicillin, and a 
proton pump inhibitor), 
 iron IV, 4 doses, 
 erythropoietin, 10,000 IU subcutaneous 
three times per week, 
 sulfamethoxazole and trimethoprim, 
double strength three times per week, for 
pneumocystis carinii prophylaxis 
(started after thrombocytopenia). 
 tube feeding. 
After administration of steroids, the 
fever resolved.  Her hospital stay was 
marked by one episode of volume overload, 
following the transfusion of two packed red 
bloods cells, which resolved with diuretics.  
The patient’s course was complicated by 
hemoptysis, attributed both to underlying 
thrombocytopenia and lupus-related alveolar 
hemorrhage.  A bronchoscopy revealed a 
diffuse alveolar hemorrhage. The bronchial 
washing was negative for Pneumocystis 
carinii pneumonia; a fungal culture revealed 
a small amount of candida. She received 
platelet transfusions and a Bilateral Positive 
Airway Pressure device. The urine culture 
grew Escherichia coli and she was treated 
with ciprofloxacin.  
Twenty-five days after admission, the 
patient was discharged home in stable 
condition with no hemoptysis and decreased 
of shortness of air.  Thrombocytopenia had 
stabilized.  The diffuse alveolar hemorrhage 
on chest x-ray and perimyocarditis on 2D 
echo were stable and unchanged.  She was 
discharged on 60mg/day of prednisone, 
500mg of mycophenolate mofetil daily with 
a plan to increase the dose to twice daily, 
hydroxychloroquine sulfate 200mg twice 
daily, a fourth dose of rituximab, erytho-
poetin 10,000 IU subcutaneous three times 
per week, and pioglitazone hydrochloride 
15mg daily with diabetic education for 
steroid-induced hyperglycemia.  One month 
after receiving her fourth dose of rituximab 
and while taking prednisone 40mg/day, her 
platelet count had risen to 150,000. 
 
Discussion 
Diagnostic issues.  Our patient satisfied 
5 of 11 American College of Rheumatology 
criteria for systemic lupus erythematosus (4 
or more being required for a diagnosis).2  
Conventional laboratory markers (a raised 
ESR and C-reactive protein hypocomple-
mentemia, high-titer ANA, and multi-organ 
damage) indicated that her lupus was active 
at the time of presentation with her acute 
illness.3-5  
A severe immune thrombocytopenic 
purpura (ITP) was associated with her lupus.  
She had no history of drug-induced 
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thrombocytopenia, and a negative blood 
smear and bone marrow biopsy. Other 
causes of thrombocytopenia (HIV, HCV) 
also were negative.  She also had positive 
antiplatelet antibodies.6,7   
Several potential causes of 
thrombocytopenia in patients with SLE are 
noted. The major mechanism is 
immunoglobulin binding to platelets 
followed by phagocytosis in the spleen, as in 
ITP.8 Membrane glycoproteins (GP) are 
most often the target of such antibodies 
(e.g., GP IIb/IIIa), but anti-HLA specificity 
also occurs.9 Antigen-dependent B cell 
development in lymphoid tissues is 
influenced by binding of CD40 on B cells to 
CD40-ligand on activated T cells. The 
finding of autoantibodies to CD40-ligand in 
patients with SLE, ITP, and Antiphos-
pholipid Antibody Syndrome, but not in the 
serum of healthy blood donors suggests that 
interference with T cell and B cell 
interaction may play a role in the 
development of thrombocytopenia.10 SLE 
patients with thrombocytopenia are more 
likely to have associated significant organ 
damage to the heart, kidneys, and the central 
nervous system.1 
An autoimmune hemolytic anemia 
(AIHA) can be associated with SLE and 
ITP.11 Our patient had a high LDH and a 
positive direct Coomb’s test, but she did not 
have low haptoglobin and her peripheral 
blood smear did not show spherocytosis.12 
The possibility of Evans syndrome also was 
suggested with both autoimmune thrombo-
cytopenia and autoimmune hemolytic 
anemia, which may precede the onset of 
SLE5, but our patient presented 
simultaneously with SLE, ITP, and possible 
AIHA. 
 
Implications for treatment.  Among 
patients with co-existent SLE and ITP 
reported in the literature, the most 
commonly employed treatment was 
prednisone (1 mg/kg per day in divided 
doses).13,14 Most patients responded within 
one to eight weeks.15  High-dose dexameth-
asone and high-dose methylprednisolone 
also are being investigated.16-19 If there is no 
significant increase in the platelet count 
within one to three weeks or side effects are 
intolerable, the following options may be 
considered.  The order in which they are 
used depends in part upon the severity of the 
thrombocytopenia and the presence or 
absence of other manifestations of SLE. 
 
1. Azathioprine (0.5 to 2 mg/kg per day).15 
2. Cyclophosphamide, given as daily oral 
or intravenous pulse therapy. 
Intravenous pulse cyclophosphamide is 
preferred in patients who also have 
severe active lupus nephritis. In one 
report of six such patients, all had 
normal platelet counts within 2 to 18 
weeks after the onset of pulse 
cyclophosphamide.20  
3. Intravenous immunoglobulin.  This 
treatment is effective and may be 
preferred to azathioprine or cyclo-
phosphamide when a rapid rise in 
platelet count is necessary (as in the 
patient who is actively bleeding or 
requires emergent surgery).21 
4. Mycophenolate mofetil.  This treatment 
may be useful in the patient refractory to 
other medical therapy.22 Due to the fact 
that our patient had proteinuria and an 
active urine sediment, but was not a 
candidate for renal biopsy due to 
thrombocytopenia, mycophenolate mo-
fetil was chosen due to the published 
literature demonstrating efficacy in 
treating lupus nephritis.19 
5. Rituximab 375 mg/m2 IV approximately 
once weekly for four consecutive 
weeks.23  Rituximab has been used to 
treat ITP in patients without SLE who 
were refractory to other treatments and 
this B lymphocyte depleting approach 
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may be beneficial for other 
manifestations of lupus.24 
6. Splenectomy.  Splenectomy can raise the 
platelet count, but it does not produce a 
durable remission of thrombocytopenia 
reliably.  Relapse following splenectomy 
may occur and has been noted at varying 
times up to 54 months after surgery.25 
Patients with persistent thrombocyto-
penia after splenectomy subsequently 
may respond to azathioprine, cyclophos-
phamide, rituximab, IVIG, danazol26,27, 
or vincristine28. 
 
Conclusion  
In summary, our patient had active SLE 
with hypocomplementemia, ITP, and 
possible AIHA. Therapy with high-dose 
corticosteroids, mycophenolate mofetil, 
hydroxychloroquine, IVIG, and four doses 
of rituximab were effective in stabilizing her 
nephritis, perimyocarditis, transaminitis, and 
thrombocytopenia.  
 
References 
1
 Wheeler CA, Calhoun L, Blackall DP. 
Warm reactive autoantibodies: Clinical 
and serologic correlations. Am J Clin 
Pathol 2004; 122:680-685. 
2
 Tan EM, Cohen AS, Fries JF, et al. The 
1982 revised criteria for the classification 
of systemic lupus erythematosus.  Arthritis 
Rheum 1982; 25:1271-1277. 
3
 Liang MH, Socher SA, Larson MG, Schur 
PH.  Reliability and validity of six systems 
for the clinical assessment of disease 
activity in systemic lupus erythematosus.  
Arthritis Rheum 1989; 32:1107-1118. 
4
 Gladman DD, Ibañez D, Urowitz MB.  
Systemic lupus erythematosus disease 
activity index 2000.  J Rheumatol 2002; 
29:288-291. 
5
 George JN, Woolf SH; Raskob GE, et al. 
Idiopathic thrombocytopenic purpura: A 
practice guideline developed by explicit 
methods for the American Society of 
Hematology.  Blood 1996; 88:3-40. 
6
 Cines DB, Bussel JB. How I treat 
idiopathic thrombocytopenic purpura 
(ITP).  Blood 2005; 106:2244-2251. 
7
 Pujol M, Ribera A, Vilardell M, Ordi J,  
Feliu E. High prevalence of platelet 
autoantibodies in patients with systemic 
lupus erythematosus. Br J Haematol 1995; 
89:137-141.  
8
 Michel M, Lee K, Piette JC,  et al.  Platelet 
autoantibodies and lupus-associated 
thrombocytopenia.  Br J Haematol 2002; 
119:354-358. 
9
 Nakamura M, Tanaka Y,  Satoh T, et al. 
Autoantibody to CD40 ligand in systemic 
lupus erythematosus: Association with 
thrombocytopenia but not thrombo-
embolism. Rheumatology (Oxford) 2006; 
45:150-156. 
10
 Ziakas PD, Giannouli S, Zintzaras E, 
Tzioufas AG, Voulgarelis M.  Lupus 
thrombocytopenia: Clinical implications 
and prognostic significance.  Ann Rheum 
Dis 2005; 64:1366-1369. 
11
 Marchand A, Galen RS, Van Lente F.  The 
predictive value of serum haptoglobin in 
hemolytic disease. JAMA 1980; 243:1909-
1911. 
12
 Schur P, Berliner N. Hematologic 
manifestations of systemic lupus 
erythematosus in adults. http:// 
www.uptodate.com/online/content/topic.d
o?topicKey=lupus/4726&selectedTitle=8~
150&source=search_result. Accessed:  
January 12, 2009. 
13
 Blanchette V, Freedman J, Garvey B.  
Management of chronic immune 
thrombocytopenic purpura in children and 
adults. Semin Hematol 1998; 35(1 Suppl 
1):36-51. 
14
 Goebel, KM, Gassel, WD, Goebel, FD. 
Evaluation of azathioprine in autoimmune 
thrombocytopenia and lupus erythema-
tosus.  Scand J Haematol 1973; 10:28-34. 
Kansas Journal of Medicine 2009                                                       Systemic Lupus Erythematosus 
47 
 
15
 Boumpas DT, Barez S, Klippel JH, Balow 
JE.  Intermittent cyclophosphamide for the  
treatment of autoimmune thrombocyto-
penia in systemic lupus erythematosus. 
Ann Intern Med 1990; 112:674-677. 
16
 Borst F, Keuning JJ, van Hulsteijn H, 
Sinnige H, Vreugdenhil G. High-dose 
dexamethasone as a first- and second-line 
treatment of idiopathic thrombocytopenic 
purpura in adults. Ann Hematol 2004; 
83:764-768.  
17
 Mazzucconi MG, Fazi P, Bernasconi S, et 
al. Therapy with high-dose dexamethasone 
(HD-DXM) in previously untreated 
patients affected by idiopathic 
thrombocytopenic purpura: A GIMEMA 
experience.  Blood 2007; 109:1401-1407.  
18
 Alpdogan O, Budak-Alpdogan T, Ratip S, 
et al. Efficacy of high-dose 
methylprednisolone as a first-line therapy 
in adult patients with idiopathic 
thrombocytopenic purpura. Br J Haematol 
1998; 103:1061-1063. 
19
 Kapitsinou P, Boletis J, Skopouli F, Boki 
KA, Moutsopoulos HM. Lupus nephritis: 
Treatment with mycophenolate mofetil. 
Rheumatology (Oxford) 2004; 43;377-
380. 
20
 Maier WP, Gordon DS, Howard RF, et al. 
Intravenous immunoglobulin therapy in 
systemic lupus erythematosus-associated 
thrombocytopenia.  Arthritis Rheum 1990; 
33:1233-1239. 
21
 Vasoo S, Thumboo J, Fong KY. 
Refractory immune thrombocytopenia in 
systemic lupus erythematosus: Response 
to mycophenolate mofetil. Lupus 2003; 
12:630-632. 
22
 Looney RJ.  B cell-targeted therapy in 
diseases other than rheumatoid arthritis. J 
Rheumatol Suppl 2005; 73:25-28. 
23
 Braendstrup P, Bjerrum OW, Nielsen OJ, 
et al. Rituximab chimeric anti-CD20 
monoclonal antibody treatment for adult 
refractory idiopathic thrombocytopenic 
purpura. Am J Hematol 2005; 78:275-280. 
24
 Hall S, McCormick JL Jr, Greipp PR, 
Michet CJ Jr, McKenna CH.  Splenectomy 
does not cure the thrombocytopenia of 
systemic lupus erythematosus.  Ann Intern 
Med 1985; 102:325-328. 
25
 You YN, Tefferi A, Nagorney DM. 
Outcome of splenectomy for 
thrombocytopenia associated with 
systemic lupus erythematosus.  Ann Surg 
2004; 240:286-292. 
26
 Vesely SK, Perdue JJ, Rizvi MA, Terrell 
DR, George JN. Management of adult 
patients with persistent idiopathic 
thrombocytopenic purpura following 
splenectomy: A systematic review.  Ann 
Intern Med 2004; 140:112-120. 
27
 Ahn YS, Harrington WJ, Seeman RC, 
Eytel CS. Vincristine therapy of idiopathic 
and secondary thrombocytopenias. N Engl 
J Med 1974; 291:376-380. 
28
 Cheng Y, Wong RS, Soo YO, et al. Initial 
treatment of immune thrombocytopenic 
purpura with high-dose dexamethasone. N 
Engl J Med 2003; 349:831-836. 
 
Keywords:  systemic lupus erythematosus, 
autoimmune thrombocytopenic purpura, 
autoimmune hemolytic anemia 
